Ultime notizie per QuidelOrtho (NASDAQ:QDEL) Azioni

QuidelOrtho

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Quidel

Gastrointestinal biomarker tests enhance patient diagnosis of&nbsp;IBD and pancreatic insufficiency on leading clinical chemistry platforms

News

QDEL

QuidelOrtho And BÜHLMANN Expand Access To Fecal Biomarker Testing With Integration Of Turbo Assays On VITROS Platforms

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.
Shares of CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/crwd/earnings">reported first-quarter results.</a>
CrowdStrike posted better-than-expected earnings for the first quarter and also raised its full-year guidance. However, the company said it expects second-quarter revenue to be between $1.145 billion and $1.152 billion versus estimates of $1.23 billion. The company anticipates second-quarter adjusted earnings of 82 cents to 84 cents per share versus estimates of 92 cents per share.
CrowdStrike shares dipped 7% to $454.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Asana, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) shares dipped 8.4% to $17.40 in today's pre-market trading after the company reported first-quarter results.</li>
<li>Outset Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) declined 6.8% to $18.09 in pre-market trading. Outset Medical named Renee Gaeta as CFO, effective immediately.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) declined 5.5% to $59.01 in pre-market trading. Merus priced $300 million public offering of 5,263,158 common shares at $57 per share.</li>
<li>Quidelortho Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares declined 4.3% to $29.00 in pre-market trading.</li>
<li>ATAI Life Sciences NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) fell 3.4% to $2.27 in pre-market trading after declining more than 5% on Tuesday.</li>
<li>Doximity Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) fell 2.7% to $52.06 in pre-market trading after gaining around 4% on Tuesday.</li>
</ul>
Now Read This:<a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen"> </a>
<ul class="wp-block-list">
<li><a href="Cramer: Should've Told Investors To 'Pull The Trigger' On Trade Desk, Can't Believe 'How Low' Gentex Has Fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ASAN

ATAI

CRWD

DOCS

MRUS

CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

UBS analyst Lu Li maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Neutral and lowers the price target from $45 to $29.

Price Target

Analyst Ratings

UBS Maintains Neutral on QuidelOrtho, Lowers Price Target to $29

<h3>Gainers</h3>
<ul>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) shares rose 39.1% to $35.96 during Thursday's regular session. The company's market cap stands at $2.4 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock increased by 38.08% to $6.54. The company's market cap stands at $355.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock increased by 32.83% to $15.6. The company's market cap stands at $276.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) stock increased by 24.11% to $14.41. The market value of their outstanding shares is at $481.3 million. As per the press release, Q1 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock moved upwards by 22.84% to $2.85. The market value of their outstanding shares is at $107.1 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) stock increased by 21.64% to $6.88. The company's market cap stands at $343.6 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock fell 74.5% to $0.12 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 69.32% to $0.16. The company's market cap stands at $20.5 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock decreased by 64.04% to $0.11. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 43.31% to $0.23. The market value of their outstanding shares is at $11.8 million. </li>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) stock fell 29.1% to $1.17. The market value of their outstanding shares is at $25.3 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares fell 28.83% to $3.44. The market value of their outstanding shares is at $123.9 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVB

AXDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CYRX

DCTH

GNLX

NCNA

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

QuidelOrtho shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Jefferies upgraded the stock from Hold to Buy and announced a $44 price target.

Jefferies analyst Tycho Peterson upgrades QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) from Hold to Buy and announces $44 price target.

Upgrades

Jefferies Upgrades QuidelOrtho to Buy, Announces $44 Price Target

U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of Groupon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) rose sharply during Thursday's session after the company reported <a href="https://in.benzinga.com/news/earnings/25/05/45285163/groupon-q1-billings-sees-double-digit-growth-in-north-america-guides-q2-above-consensus">better-than-expected first-quarter financial results.</a>
The company reported revenue of $117.2 million, beating estimates of $115.5 million, according to Benzinga Pro. Groupon reported an EPS of 18 cents, versus estimates for a loss of 11 cents.
Groupon shares jumped 26.3% to $21.45 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>SunOpta Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKL#NASDAQ">STKL</a>) shares jumped 41.3% to $6.40 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates. Additionally, the company announced a $25 million share repurchase program.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) gained 36.5% to $72.00 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) rose 33.3% to $143.75 after the company reported strong first-quarter results and raised its FY25 sales guidance.</li>
<li>LegalZoom.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) gained 30% to $9.42 after the company reported better-than-expected first-quarter sales results and issued second-quarter sales guidance with its midpoint above estimates. Also, the company issued FY25 sales guidance above estimates.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 29% to $245.00.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) gained 29% to $33.30 following upbeat quarterly earnings.</li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) gained 24% to $9.86 after the company reported better-than-expected first-quarter financial results.</li>
<li>D-Wave Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NASDAQ">QBTS</a>) rose 22% to $8.41 after the company reported better-than-expected quarterly financial results.</li>
<li>Revolution Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVMD#NASDAQ">RVMD</a>) jumped 15.5% to $43.39 following quarterly results.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 15.5% to $350.42 after the company reported better-than-expected first-quarter financial results.</li>
<li>EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) rose 14.8% to $182.95 after the company reported better-than-expected first-quarter financial results and issued second-quarter adjusted EPS guidance above estimates. Also, the company raised its FY25 guidance.</li>
<li>Watts Water Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) gained 10.7% to $234.35 following strong quarterly results.</li>
<li>SharkNinja, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) surged 10.1% to $89.36 after the company reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS guidance above estimates.</li>
<li>Axon Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) rose 9.6% to $659.40 after the company reported better-than-expected first-quarter financial results and raised FY25 sales guidance.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) rose 9.1% to $282.76 after the company reported better-than-expected first-quarter financial results.</li>
<li>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) jumped 7.5% to $9.20 following quarterly results.</li>
<li>Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) gained 7.6% to $9.26 after the company reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS guidance.</li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) gained 7% to $2,418.76 after the company reported better-than-expected first-quarter financial results.</li>
<li>Paycom Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) rose 5.9% to $242.05 following upbeat quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45284390/how-to-earn-500-a-month-from-mckesson-stock-ahead-of-q4-earnings">How To Earn $500 A Month From McKesson Stock Ahead Of Q4 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

ALVO

AXON

CVNA

DAVE

EPAM

GRPN

MELI

PAYC

QBTS

RVMD

SEZL

STKL

VTRS

Groupon Posts Upbeat Earnings, Joins Axon Enterprise, Warner Bros. Discovery, MercadoLibre And Other Big Stocks Moving Higher On Thursday

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) affirms FY2025 Adj EPS guidance from $2.07-$2.57 to $2.07-$2.57 vs $3.25 analyst estimate. Affirms FY2025 sales outlook from $2.60 billion-$2.81 billion to $2.60 billion-$2.81 billion vs $2.81 billion estimate.

Guidance

QuidelOrtho Affirms FY2025 Adj EPS Guidance of $2.07-$2.57 vs $3.25 Est; Affirms FY2025 Sales Guidance of $2.60B-$2.81B vs $2.81B Est

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) reported quarterly earnings of $0.74 per share which beat the analyst consensus estimate of $0.11 by 572.73 percent. This is a 68.18 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $692.80 million which beat the analyst consensus estimate of $622.32 million by 11.33 percent. This is a 2.56 percent decrease over sales of $711.00 million the same period last year.

Earnings

Earnings Beats

QuidelOrtho Q1 Adj. EPS $0.74 Beats $0.11 Estimate, Sales $692.80M Beat $622.32M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

Earnings Scheduled For May 7, 2025

JP Morgan analyst Casey Woodring maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Underweight and lowers the price target from $38 to $25.

JP Morgan Maintains Underweight on QuidelOrtho, Lowers Price Target to $25

In the latest quarter, 4 analysts provided ratings for QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.75, a high estimate of $61.00, and a low estimate of $43.00. A 1.15% drop is evident in the current average compared to the previous average price target of $50.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1739476846_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive QuidelOrtho. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$43.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to QuidelOrtho. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of QuidelOrtho compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for QuidelOrtho's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into QuidelOrtho's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/QDEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on QuidelOrtho analyst ratings.</a>
<h2>Get to Know QuidelOrtho Better</h2>
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
<h3>Unraveling the Financial Story of QuidelOrtho</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: QuidelOrtho's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.27%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: QuidelOrtho's net margin excels beyond industry benchmarks, reaching -2.74%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): QuidelOrtho's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.63% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): QuidelOrtho's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.29%, the company showcases efficient use of assets and strong financial health.
Debt Management: QuidelOrtho's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where QuidelOrtho Stands With Analysts

QuidelOrtho shares are trading higher after the company reported better-than-expected Q4 financial results. Also, UBS maintained a Neutral rating ont he stock and raised its price target from $43 to $45.

RBC Capital analyst Conor McNamara maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Outperform and lowers the price target from $64 to $61.

RBC Capital Maintains Outperform on QuidelOrtho, Lowers Price Target to $61

UBS analyst John Sourbeer maintains QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) with a Neutral and raises the price target from $43 to $45.

UBS Maintains Neutral on QuidelOrtho, Raises Price Target to $45

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) is looking for FY2025 Adj EPS of $2.07-$2.57 vs $2.44 analyst estimate. sees sales of $2.600 billion-$2.810 billion vs $2.76 billion analyst estimate.

QuidelOrtho Sees FY2025 Adj EPS $2.07-$2.57 vs $2.44 Est; Sees Sales $2.600B-$2.810B vs $2.76B Est

QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.59 by 6.78 percent. This is a 46.15 percent decrease over earnings of $1.17 per share from the same period last year. The company reported quarterly sales of $707.80 million which beat the analyst consensus estimate of $699.16 million by 1.24 percent. This is a 4.69 percent decrease over sales of $742.60 million the same period last year.

QuidelOrtho Q4 2024 Adj EPS $0.63 Beats $0.59 Estimate, Sales $707.80M Beat $699.16M Estimate

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BXMT

CAMT

CGNX

CHEF

CNCK

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PEGA

PLMR

PODC

PXLW

PYPD

QMCO

QTWO

Earnings Scheduled For February 12, 2025

<h3>Gainers</h3>
<ul>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares increased by 134.7% to $4.46 during Tuesday's pre-market session. The company's market cap stands at $37.9 million. </li>
<li>Eterna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) shares increased by 65.04% to $0.51. The market value of their outstanding shares is at $26.2 million. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares moved upwards by 30.29% to $0.28. The company's market cap stands at $45.6 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock increased by 18.72% to $2.98. The company's market cap stands at $39.6 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock rose 17.56% to $5.02. The market value of their outstanding shares is at $5.6 million. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock moved upwards by 15.94% to $0.83. The market value of their outstanding shares is at $189.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) stock decreased by 41.8% to $3.84 during Tuesday's pre-market session. The company's market cap stands at $6.6 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined by 25.89% to $1.46. The company's market cap stands at $5.8 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares decreased by 23.23% to $0.62. The company's market cap stands at $1.9 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares decreased by 17.99% to $3.01. The company's market cap stands at $4.3 million. </li>
<li>QuidelOrtho (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) stock decreased by 16.5% to $37.25. The company's market cap stands at $2.5 billion. </li>
<li>Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) shares decreased by 15.5% to $1.8. The market value of their outstanding shares is at $23.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

ATPC

AVGR

ERNA

KAPA

PHIO

PIII

PRTG

SLRX

VXRT

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

QuidelOrtho Sees Prelim Q4 Revenue $702M-$707M Vs $698.041M Est.

Press Releases

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

Comments

QuidelOrtho

Notizie

Ultime notizie per QuidelOrtho (NASDAQ:QDEL) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO